title: Ten-year surveillance of pneumococcal infections in Temuco, Chile: implications for vaccination strategies.
abstract: We monitored Streptococcus pneumoniae serotypes causing invasive infections in patients admitted to one hospital in southern Chile during a 10-year period (1994 to 2004). All specimens isolated from patients with invasive S. pneumoniae infections were serotyped at the CDC in Atlanta, GA. A total of 508 isolates belonged to 58 serotypes. There were 95 infections in patients <2 years old, 33 infections in patients 2 to 4 years old, 61 infections in patients 5 to 14 years old, 66 infections in patients 15 to 44 years old, 134 infections in patients 45 to 64 years old, and 120 infections in patients >or=65 years old. The 10 serotypes isolated with the highest frequency in all groups were, in decreasing order, 1, 3, 14, 5, 19F, 6B, 7F, 12F, 23F, and 6A. The 10 most frequent isolates in children under 2 years of age were 1, 6B, 14, 19F, 5, 23F, 6A, 9V, and 7F. In patients >or=65 years old, the most common serotypes were 3, 7F, 1, 14, 19A, 23F, 19F, 35B, 4, and 5. Penicillin resistance was detected in 14 (2.7%) clinical specimens isolated since 1998, with 13 resistant strains identified since 2001. Vaccine coverage for the 7-valent conjugate vaccine was 42% for children <2 years of age. This study is important for the design of vaccines for this region and to evaluate public health measures to decrease pneumococcal infections.
authors: Immunology and Bacteriology Laboratory, Hospital Dr. Hernán Henriquez A, Temuco, Chile.
authors: Jaime
authors: J
authors: Inostroza
authors: Vijna
authors: V
authors: Illesca
authors: Patricia
authors: P
authors: Reydet
authors: Ana Maria
authors: AM
authors: Vinet
authors: Gonzalo
authors: G
authors: Ossa
authors: Sergio
authors: S
authors: Muñoz
authors: Terry
authors: T
authors: Thompson
authors: Ricardo U
authors: RU
authors: Sorensen
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002677:Chile / Q000453:epidemiology; D024881:Drug Resistance, Bacterial; D006801:Humans; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D011159:Population Surveillance; D012703:Serotyping; D013048:Specimen Handling; D013296:Streptococcus pneumoniae / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification; D013997:Time Factors; D014505:Urban Population / Q000639:trends*; D014611:Vaccination; D018074:Vaccines, Conjugate
chemical_list: D000900:Anti-Bacterial Agents; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate